Xcout IntelBionano Genomics, Inc.
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Subscribe to see Bionano Genomics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Bionano Genomics, Inc. at a glance
Bionano Genomics, Inc. is a biotech company headquartered in San Diego, United States. It is publicly listed (BNGO) with a market capitalisation of $16.5M. Xcout tracks 17 named people at Bionano Genomics, Inc., including Albert A. Luderer (Chairman, Interim CEO, Interim President & Interim Principal Financial Officer).
Bionano Genomics, Inc. leadership
- Albert A. LudererChairman, Interim CEO, Interim President & Interim Principal Financial Officer
- Albert LudererChairman & Interim CEO
- Mark OldakowskiChief Operating Officer
- Alex HastieChief Scientific Officer
- Mark AdamchakVP of Accounting, Principal Accounting Officer & Controller
- Cory KreeckGlobal Head of People Operations
11 more named people on record for Bionano Genomics, Inc., with roles, board committees and tenure — see the full roster →
Bionano Genomics, Inc. funding rounds on record
The most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $53M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Bionano Genomics, Inc. competitors
A few of Bionano Genomics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Illumina, Inc. specializes in delivering advanced sequencing and array technologies designed for genetic and genomic examination. These offerings cater to a diverse array of markets, fostering the widespread use of genomic insights across both research laboratories and clinical environments. Key application areas include life sciences, cancer diagnostics, reproductive medicine, agricultural science, and various nascent fields. The company's portfolio encompasses specialized instrumentation and associated consumables vital for genetic analysis. Additionally, it offers comprehensive genotyping and sequencing services, extends instrument maintenance contracts, and engages in development and licensing partnerships, alongside providing cancer screening services. Illumina's client base is extensive, comprising genomic research facilities, universities, state-funded laboratories, and healthcare providers. It also serves pharmaceutical firms, biotechnology companies, commercial molecular diagnostics providers, and businesses focused on consumer genomics. Globally, Illumina distributes its products through direct sales channels in North America, Europe, Latin America, and the Asia-Pacific. Furthermore, it leverages third-party life-science distributors to reach markets across Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Biotrove, Inc., founded in 1997, is a developer and manufacturer of genomic analysis instruments, consumables, and technology platforms such as OpenArray. The company provides systems and services for molecular diagnostics, high-throughput screening, drug discovery, and life sciences research.
Olink Proteomics provides high-throughput protein biomarker analysis products, instruments, software, and analysis services for life science research and drug development. Utilizing its proprietary Proximity Extension Assay (PEA) technology and next-generation sequencing, the company serves researchers and pharmaceutical organizations focused on biomarker discovery and precision medicine.
OraSure Technologies, Inc., together with its subsidiaries including DNA Genotek, develops and provides non-invasive diagnostic tests and biological sample collection tools. The company serves individuals, healthcare providers, and researchers by offering solutions for infectious disease detection, genomics, metabolomics, and microbiome research.
Source BioScience is a UK-based laboratory services company providing genomics, DNA sequencing, molecular diagnostics, and pathology-related testing. It serves pharmaceutical and biotechnology companies, healthcare organizations, research institutions, and other life-science customers.
GenDx specializes in molecular diagnostics for transplantation and personalized healthcare, providing pre- and post-transplant reagents, NGS-based typing assays, and analysis software. The company serves diagnostic laboratories, transplant centers, and researchers by offering products and technical support for HLA typing, chimerism monitoring, and related applications.
Get Bionano Genomics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Bionano Genomics, Inc. in Xcout Intel
- 17 named people with titles, LinkedIn and board committees
- 4 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access